文献速递产科母胎医学

基于超声与游离DNA的一线孕期风险筛查对比联合筛查:一项随机对照试验

First-trimester risk assessment based on ultrasound and cell-free DNA vs combined screening: a randomized controlled trial.
PubMed 文献 · Ultrasound Obstet Gynecol · 2018-03-04

该随机对照试验将1518例孕11-13周超声正常的单胎孕妇随机分为两组,分别采用早孕期联合筛查(FTCS)或详细超声联合cfDNA分析进行21三体风险筛查。结果显示超声+cfDNA组21三体风险均未超过1:100(95%CI 0.0-0.5%),FTCS组为2.5%(95%CI 1.5-3.9%),前者假阳性率显著降低。

要点

  • 超声+cfDNA组21三体风险均未超过1:100(95%CI 0.0-0.5%),假阳性率显著低于FTCS组。
  • FTCS组17例风险高于1:100,占该组2.5%(95%CI 1.5-3.9%)。
  • 该方案可省去孕妇血清游离β-hCG和妊娠相关血浆蛋白A检测。

核心结论

  • 包含详细超声检查及NT测量、随后进行cfDNA检测的早孕期21三体风险评估,与FTCS相比假阳性率显著降低。
  • 该方案可省去孕妇血清游离β-人绒毛膜促性腺激素和妊娠相关血浆蛋白A检测。

研究设计与样本

  • 随机对照试验,纳入孕11-13周超声正常(NT≤3.5 mm且无胎儿缺陷)的单胎孕妇。
  • 1518例孕妇中31例(2.0%)因NT>3.5 mm和/或胎儿缺陷不符合随机化条件。
  • 排除拒绝随机化87例及胎死宫内和失访24例后,688例随机分入FTCS组,688例分入超声+cfDNA分析组。
  • FTCS组采用最新英国胎儿医学基金会算法评估非整倍体风险。
  • 超声+cfDNA组基于超声所见和cfDNA分析评估风险,并额外采集一管血以备cfDNA分析无信息时行FTCS。

主要发现

  • 两组孕妇年龄、孕周、体重和BMI、种族、辅助生殖使用及吸烟情况无差异。
  • 超声+cfDNA组21三体中位风险为1/10000,无病例风险超过1:100(95%CI 0.0-0.5%)。
  • FTCS组21三体中位风险为1/3787,17例风险高于1:100,占该组2.5%(95%CI 1.5-3.9%)。
  • 主要结局为21三体筛查假阳性率,定义为核型非21三体且21三体风险>1:100,不论风险计算方法。
  • 结果采用Clopper-Pearson法计算95%CI进行比较。

关键数值与推荐

  • 21三体风险>1:100定义为筛查阳性(假阳性判定标准)。
  • 超声+cfDNA组无病例风险超过1:100(95%CI 0.0-0.5%)。
  • FTCS组风险高于1:100者占2.5%(95%CI 1.5-3.9%)。

临床怎么用

  • 早孕期风险筛查可包括详细超声检查、NT测量及随后cfDNA检测。
  • 该方案可省去孕妇血清游离β-人绒毛膜促性腺激素和妊娠相关血浆蛋白A检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This was a randomized controlled trial to compare risk assessment by first-trimester combined screening (FTCS) with an approach that combines a detailed ultrasound examination at 11-13 weeks' gestation and cell-free DNA (cfDNA) analysis. METHODS: Pregnant women with a normal first-trimester ultrasound examination at 11-13 weeks' gestation (fetal nuchal translucency (NT) ≤ 3.5 mm and no fetal defects) were randomized into one of two groups. In the first group, risk of aneuploidy was assessed using FTCS based on the most recent UK Fetal Medicine Foundation algorithm. In the second group, risk assessment was based on ultrasound findings and cfDNA analysis. An additional tube of blood was collected for FTCS in case the cfDNA analysis was uninformative. Primary outcome was false-positive rate in screening for trisomy 21. A case was considered false positive if the karyotype was not trisomy 21 and if the risk for trisomy 21 was >1:100, irrespective of the method of risk calculation. Results were compared using 95% CIs using the Clopper-Pearson method. RESULTS: Between October 2015 and December 2016, 1518 women with singleton pregnancy underwent first-trimester screening. Thirty-one (2.0%) pregnancies were not eligible for randomization due to increased NT (> 3.5 mm) and/or fetal defect. After exclusion of women who declined randomization (n = 87) and cases of fetal death and loss to follow-up (n = 24), 688 pregnancies were randomized into the FTCS arm and 688 into the ultrasound + cfDNA analysis arm. There were no differences in maternal and gestational age, maternal weight and BMI, ethnicity, use of assisted reproduction and cigarette smoking between the two arms. In the ultrasound + cfDNA analysis arm, median risk for trisomy 21 was 1 in 10 000. None of the cases had a risk above 1: 100 (95% CI, 0.0-0.5%). In the FTCS arm, the median risk for trisomy 21 was 1 in 3787 and in 17 cases, the risk was higher than 1:100, which corresponds to 2.5% (95% CI, 1.5-3.9%) of the FTCS study-arm population. CONCLUSION: Our study has shown that first-trimester risk assessment for trisomy 21 that includes a detailed ultrasound examination as well as NT measurement and is followed by cfDNA testing is associated with a significant reduction in the false-positive rate compared with FTCS. This approach obviates the need for maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A in screening for fetal aneuploidy. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Kagan KO, Sroka F, Sonek J, et al. First-trimester risk assessment based on ultrasound and cell-free DNA vs combined screening: a randomized controlled trial. Ultrasound Obstet Gynecol. 2018. PMID: 28925570. doi:10.1002/uog.18905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。